INTRODUCTION AND OBJECTIVES: Transrectal biopsy is
plagued by an increasing rate of serious infection, despite use of recommended fluoroquinolone antibiotics. Transperineal biopsy (TPB), on the other hand, has been associated with an exceedingly low rate of serious infection. The aim of this study was to determine the rate of hospital admissions for infection after transperineal biopsy of prostate.
METHODS: Patients underwent transperineal biopsy of the prostate (TPB) between May 2012 and October 2016 by a private group urology practice, at multiple hospitals across Melbourne. A standard brachytherapy template grid was used, taking a number of samples from left and right prostate posterior, mid and anterior regions. Some patients had extra core biopsies taken from target areas suspicious of cancer identified on prior MRI. Data collected from these patients were entered into an ethics approved prospective database including prophylactic antibiotics used and post operative complications.
RESULTS: 1359 consecutive patients underwent TPB. Initially patients were treated with quinolone prophylaxis and then later patients received cephazolin only. 1030 (75.8%) had single dose IV cephazolin, 388 (28.6%) had an oral quinolone with IV cephazolin, 107 (7.9%) had IV ceftriaxone and 2 (0.1%) had IV clindamycin, 2 (0.1%) had IV meropenem and 1 (0.1%) had IV vancomycin prophylaxis. Routine practice shifted from use of quinolones to cephazolin during the study period. 25 (1.8%) patients developed acute urinary retention and 1 patient was treated in the community with oral antibiotics for prostatitis. No patients were readmitted to hospital with infection.
CONCLUSIONS: Sepsis post TPB is an exceedingly rare complication, with a 0% rate in this large prospective multicentre cohort. It is safe to use single dose cephazolin only as antibiotic prophylaxis prior to TPB, negating the need for quinolones. This study supports the current Australian Therapeutic Guidelines recommendation for TPB prophylaxis. Whether any antibiotic prophylaxis is needed at all for TPB is the subject of a future study. INTRODUCTION AND OBJECTIVES: mpMRI enables a new way to stratify prostate cancer patients through visualisation of a target to biopsy. However, prostate cancer is heterogeneous, even within the same focus. We aimed to determine deploying the needle to the centre of a mpMRI lesion would reflect the true risk of that lesion. Our study involved a unique cohort of men in whom a pre-biopsy mpMRI was carried out prior to Transperineal Prostate Mapping biopsies taken every 5mm within the PROMIS trial.
METHODS: 94 patients included in this analysis comprised the pilot phase of the Prostate MRI Imaging Study (NCT01292291) investigating accuracy of mpMRI against standard of care with 3D 5mm TPMbiopsies as the reference test. All patients were biopsy-naive with a PSA below 15ng/ml, referred for suspicion of prostate cancer. Prior to biopsy, all patient underwent 1.5T mpMRI with standardized protocol (T2W, DWI , DCE) which were reported on a Likert scale, blinded to subsequent histology results. Patients then underwent TPM-biopsies blinded to the mpMRI findings so that the whole prostate was sampled every 5mm. Cores were separately labelled and oriented in space. A 3D digital map of the gland was reconstructed from the TPM-biopsies using in-house software. Prostates and mpMRI lesions were contoured (blind to pathology results), registered to the digital map by aligning gland boundaries. We identified the MRI lesion centroid and the locations of biopsy cores containing the maximum Gleason score of the lesion. We considered two cores in particular. First, the one closest to the centroid and second, the one with the longest maximum cancer core length. We computed the distance from these two cores to the centroid of the MRI lesion.
RESULTS: 41 patients (median PSA 6.5ng/ml, median age 62) were found to harbour cancer at TPM-biopsies in this cohort, leading to 75 MRI lesions correlated with cancer. From the centroid, the mean distance to closest maximum Gleason core was 7.8mm (+/-6.6), and to core with the maximum cancer length was 13.8mm (+/-8.3).
CONCLUSIONS: The histological tissue that harbours the highest Gleason score within a prostate cancer lesion seen on mpMRI is not consistently located near the centre. MRI-lesion-based targeting should include sampling the entire lesion with a number of cores. We previously provided estimates of lead-time for prostate cancer using archived blood samples from cohorts followed for many years without screening. We determined the association between lead-time and grade at diagnosis to provide insight into whether grade progresses or is stable over time.
e486
THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 
